Can Invion Limited (ASX: IVX) unlock new growth by taking Photosoft into pet cancer care?

Invion Limited (ASX: IVX) has launched a new partnership that could significantly shift its near-term positioning and long-term market potential. The Australian life science company has entered a funded evaluation agreement with Taiwan-based Protect Animal Health Inc. (TPE: 7850), targeting a fast-growing yet under-innovated sector: cancer therapeutics for companion animals.

Announced on October 21, 2025, the collaboration is designed to assess the potential of Invion Limited’s proprietary Photosoft platform in treating cancer in pets such as dogs and cats, marking a notable extension of the company’s focus beyond human oncology. Under the agreement, Protect Animal Health Inc. will fund and conduct laboratory and live animal studies using Invion Limited’s next-generation photosensitisers.

This move comes at a pivotal time for Invion Limited. The stock has fallen sharply over the past year—down more than 52 percent—closing at just A$0.096 on low trading volume. Market cap has dwindled to A$8.22 million, and investor sentiment remains cautious amid the absence of near-term revenue. However, the new companion animal partnership could spark renewed interest by offering faster regulatory timelines and a less capital-intensive commercialization path.

Why Invion Limited chose to enter veterinary oncology and how the Protect deal is structured

Under the terms of the agreement, Protect Animal Health Inc. will conduct a broad evaluation of Invion Limited’s Photosoft compounds through in vitro, in vivo, and companion animal studies. Invion Limited will supply the photosensitising agents from its proprietary platform but will retain full intellectual property ownership, including any discoveries or improvements resulting from the collaboration.

This structure ensures that Invion Limited maintains all upside potential while minimizing out-of-pocket risk. Importantly, the funding for the evaluation studies will come from Protect Animal Health Inc., making the collaboration non-dilutive for Invion Limited shareholders. Should the evaluation prove successful, both companies may enter a more expansive co-development agreement to govern future commercialization.

This veterinary oncology push also aligns with Invion Limited’s broader strategy to extract platform value from Photosoft through partnerships across multiple therapeutic domains. The company is already collaborating with Hanlim Pharm Co. Ltd. on oesophageal cancer and glioblastoma, and with Dr.inB Co. Ltd. on HPV-related research.

Executive Chairman and Chief Executive Officer of Invion Limited, Professor Thian Chew, stated that the Protect partnership underscores the company’s approach of using third-party collaborations to unlock new therapeutic pathways while securing external funding and expertise. He noted that the companion animal segment could offer accelerated paths to market compared to human oncology due to fewer regulatory barriers.

How big is the pet cancer therapeutics market and what strategic value does it offer Invion Limited?

Cancer remains one of the leading causes of death in pets globally. According to Invion Limited, nearly half of all dogs over the age of ten are expected to develop some form of cancer during their lifetime. Despite the prevalence, treatment options remain outdated, often relying on older chemotherapy agents that bring limited efficacy and high side-effect profiles.

This disconnect between market demand and therapeutic innovation presents a sizable opportunity for new entrants. The global pet cancer therapeutics market is expected to be worth approximately US$4.8 billion in 2024, with analysts forecasting a compound annual growth rate of 9.7 percent through 2034, potentially reaching US$12.1 billion over the next decade.

From a strategic standpoint, this segment offers Invion Limited an adjacent but synergistic growth channel. Unlike the highly regulated human drug development pathway, veterinary therapeutics often benefit from streamlined regulatory reviews, especially for platforms like Photodynamic Therapy (PDT), which are already validated in human clinical trials. This could allow Invion Limited to demonstrate commercial proof of concept more quickly in pets—laying the groundwork for larger opportunities in human health later on.

What is Photosoft and how does Invion Limited position it as a next-generation therapeutic platform?

Photosoft is Invion Limited’s proprietary photodynamic therapy (PDT) technology. The platform uses light-activated, non-toxic photosensitisers to selectively destroy diseased cells—such as tumors—while sparing healthy tissue. Unlike traditional chemotherapy or invasive surgeries, PDT aims to provide targeted efficacy with fewer systemic side effects.

The mechanism involves administering a photosensitising agent that accumulates in cancerous or infected cells. Upon exposure to a specific wavelength of light, these agents produce a localized reactive oxygen species burst, killing the target cells and stimulating immune responses. The result is a therapeutic approach that combines precision killing with immunomodulation—offering dual benefits in both oncology and infectious disease treatment.

Importantly, Invion Limited holds exclusive Photosoft commercial rights across multiple geographies and indications. For cancer, it owns licensing and distribution rights across Australia, New Zealand, and Asia Pacific, excluding China, Macau, Japan, and Taiwan. For infectious diseases and atherosclerosis, it holds territorial rights spanning Asia, Oceania, North America, and select regions globally, with some exceptions such as Russia and the Middle East.

Photosoft is already the subject of multiple collaborations and ongoing preclinical studies. Clinical development has so far been funded through non-dilutive channels, particularly via technology licensor RMW Cho Group Limited, which supports research and trial execution.

How does Protect Animal Health’s expertise enhance the partnership’s commercial potential?

Protect Animal Health Inc., listed on the Taipei Exchange under the code 7850, is a biotechnology company focused on applying human-grade innovation to animal health. The firm’s pipeline includes several high-impact veterinary therapies, including PT001, a first-in-class therapeutic cancer vaccine, and PT401, a gene therapy for canine heart disease.

The company is also actively developing a proprietary pet antibody drug platform, which adapts proven human biologics for animal use. Protect Animal Health Inc. aims to create an end-to-end ecosystem for pet wellness—spanning early diagnostics, daily chronic care, and advanced therapeutics. Its infrastructure and development track record provide Invion Limited with a capable and well-funded partner in the animal health domain.

According to Haolin Sung, Chief Executive Officer of Protect Animal Health Inc., the partnership represents a compelling opportunity due to Photosoft’s distinctive mechanism of action, which has shown promising results in both preclinical and human trials. He expressed confidence that the compound could open new treatment pathways in the underserved veterinary oncology segment.

The endorsement from a credible partner such as Protect Animal Health Inc. may also be seen as validation by institutional investors, particularly given that Invion Limited remains thinly covered by major brokerages.

What does the current stock performance indicate about retail and institutional sentiment?

Invion Limited’s share price has seen a steep decline over the past year, falling from a high near A$0.43 to its current level of A$0.096. This represents a 52 percent year-on-year drop, and a 65.7 percent decline in 2025 alone. Trading volume is low, with the most recent session registering just 2,000 shares exchanged, compared to a four-week average volume of over 108,000 shares.

With no earnings per share, zero dividend yield, and a price-to-book value ratio of 1.0 (based on a book value per share of A$0.096), Invion Limited currently ranks 192 out of 235 in the healthcare sector and 2,025 out of 2,297 on the ASX overall. These metrics place the company deep in speculative territory, likely attracting only high-risk retail investors and some biotech-focused microcap funds.

Institutional participation appears minimal, and the absence of broker coverage may further limit liquidity and visibility unless triggered by near-term catalysts such as trial readouts or licensing deals.

How could Invion’s animal health partnership shape investor expectations and future monetization strategy?

For investors, the key takeaway is that Invion Limited is actively pursuing alternative commercialization routes to unlock Photosoft’s full platform value. The Protect Animal Health Inc. agreement is not expected to generate revenue immediately, but it introduces a potentially accelerated path to market validation in a new and growing therapeutic area.

If Protect’s evaluation studies produce positive results, this could lead to a formal co-development agreement, allowing Invion Limited to tap into the rapidly expanding global veterinary therapeutics market. Moreover, successful animal data may offer corroborative evidence supporting Photosoft’s efficacy in human applications, strengthening Invion Limited’s pipeline across both regulatory domains.

However, much depends on execution. Until tangible preclinical results or commercialization terms emerge, the market may remain cautious. Yet for long-horizon investors who believe in platform plays, the company’s diversified strategy and low valuation could represent a high-risk, high-reward opportunity—especially as veterinary biotech gains more attention in both public and private markets.

What are the most important takeaways from Invion’s pivot to veterinary oncology via Protect Animal Health?

• Invion Limited (ASX: IVX) has entered a funded evaluation agreement with Taiwan’s Protect Animal Health Inc. to assess Photosoft in companion animal cancer treatment.
• The collaboration allows Protect to conduct preclinical and companion animal studies, while Invion retains full rights to Photosoft and any new IP developed under the deal.
• This move aligns with Invion’s strategy to unlock Photosoft’s value via non-dilutive partnerships across multiple indications and geographies.
• The global pet cancer therapeutics market is projected to grow from US$4.8 billion in 2024 to US$12.1 billion by 2034, making it an attractive adjacent segment.
• Photosoft™’s photodynamic therapy platform offers minimally invasive, immune-stimulating cancer treatment with applications in oncology and infectious disease.
• Protect brings strong veterinary innovation credentials, including gene therapies and pet-specific antibody platforms, to the collaboration.
• Invion’s stock has declined over 52% year-on-year, with low liquidity and minimal institutional coverage, but the pivot could re-engage investors if milestones are achieved.
• While no immediate revenue is expected, successful animal studies may accelerate Photosoft’s validation and open new commercialization pathways.